Primex Pharmaceuticals Appoints Jostein Davidsen and Angelo Colombo as Board Members
Jostein Davidsen brings over 30 years of experience from the international pharmaceutical industry, most recently serving as CEO of Acino Pharmaceuticals in Switzerland.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170503005582/en/
Mr. Davidsen was the founder of Nycomed Russia-CIS which he built up to be one of the leading pharmaceutical companies in the region, until being sold to Takeda Pharmaceuticals in 2011. Davidsen then became Corporate Officer and Head of the Emerging Markets at Takeda in Zurich. He was named the world's second most influential pharma-industry leader in Emerging Markets by pharma news service Scrip.
Angelo Colombo has 25 years of experience from the pharmaceutical sector. Recently, he was Managing Director at Corden Pharma Spa with extensive experience in the manufacture of pharmaceuticals, especially injectables.
Previously, Mr. Colombo was the Nerviano site leader for Pfizer, one of the largest pharmaceutical R&D centers for oncology in Europe. He was also General Manager at Pierrel, a leading dental anaesthetic manufacturer. In these roles, Colombo obtained FDA and EMEA approvals at all sites, built a new injectable department with the highest technology standards and developed new formulations.
Panu Paappanen, Chairman of the Board, commented: "With these appointments the board gains senior pharma executives to strengthen the strategic expertise in growing our global pharmaceutical business.”
Kari Sarvanto, CEO and Co-Founder of Primex, added: “I am delighted that we can attract experienced pharmaceutical professionals to our board, at a time when Primex is progressing to a new and exciting stage of strong and sustainable growth.”
About Primex Pharmaceuticals:
Primex Pharmaceuticals aims to become the leading global innovative anaesthesia company, and to expand in paediatric and orphan pharmaceuticals.
A portfolio of strong, trusted anaesthesia products from propofol-based products acquired from Bayer to a novel oral solution for paediatric procedural sedation, is helping patients undergo a wide range of medical procedures. Primex Pharmaceuticals continues to identify and acquire new medications that complete the ‘Triad of Anaesthesia’.
Primex Pharmaceuticals' global partner network operates in over 40 countries. The company is headquartered in Switzerland; all Primex products are manufactured in Europe. Primex Pharmaceuticals has proven underlying business operations and historically strong revenue growth.
Mr. Kari Sarvanto, Group CEO
Mobile: +41 796 162 694
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
NC-REDWOOD-SOFTWARE22.3.2018 16:01 | pressemeddelelse
Redwood Software Announces First Industry Robotic Licensing Model to Revolutionize Transparent Marketplace Pricing
L&T-TECHNOLOGY-SERVICES22.3.2018 15:36 | pressemeddelelse
German Chemical Major Covestro Awards L&T Technology Services Multi-Million Dollar ER&D Project
SAGA-FOUNDATION22.3.2018 14:02 | pressemeddelelse
The Saga Foundation Announces Its Plan to Create a Non-Anonymous, Reserve-Backed Digital Currency
CA-BOOHOO.COM22.3.2018 13:50 | pressemeddelelse
boohoo.com Celebrates the Launch of Their Spring Collection & the Zendaya Edit with a 90s Throwback Block Party!
NJ-SYNCHRONOSS22.3.2018 13:02 | pressemeddelelse
Synchronoss Renews Agreement to Power Verizon Cloud
MA-TAKEDA-PHARMACEUTICAL22.3.2018 13:02 | pressemeddelelse
Takeda Announces Publication of Final Data from ICLUSIG® (ponatinib) Pivotal Phase 2 PACE Trial in Blood
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum